SUNNYVALE, Calif., Oct. 6 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the 100,000th patient has been treated with the CyberKnife® Robotic Radiosurgery System, a non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors anywhere in the body. One in four patients treated with CyberKnife radiosurgery received treatment during Accuray's fiscal 2010, which ran July 2009 to June 2010.
Over the past five years, the average growth rate for intracranial applications, including brain tumors, arteriovenous malformations and acoustic neuromas, was 42 percent worldwide. Despite this growth, it is extracranial applications that have become the mainstay of CyberKnife usage, representing more than 50 percent of CyberKnife treatments worldwide during Accuray's fiscal 2010. The CyberKnife System is the leading radiosurgery system capable of delivering both intracranial and extracranial treatments.
Because it is also the only system that continuously tracks and automatically corrects for patient and tumor motion anywhere in the body, the CyberKnife System continues to see growth in treatments of lung and prostate cancer. The average worldwide growth rate over the past five years for CyberKnife lung treatments was 80 percent and prostate treatments was 113 percent. This strong and sustained growth demonstrates clinicians' increasing recognition of the System's unique benefits in treating tumors that move throughout treatment with respiration or other bodily functions.
"We are excited about the continued momentum and overall growth in CyberKnife adoption and usage over the past few years. With a 25 percent increase in patient treatments during our fiscal 2010 on top of an increasing base of procedures, CyberKnife radiosurgery is growing at an exponential rate, which clearly highlights the value our technology brings to cancer care," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "I would like to thank all the dedicated Accuray employees who have made this growth possible over the last few years."
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more 100,000 patients worldwide and more than 206 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to growth in clinical applications and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for the 2010 fiscal year which has been filed with the Securities and Exchange Commission on August 31, 2010. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
SOURCE Accuray Incorporated